Ets2 transcription factor in normal and neoplastic human breast tissue.

The Ets family of transcription factors regulate the expression of multiple genes involved in tumour formation and progression. The aim of this work was to test the hypothesis that the expression of Ets2 in breast cancers was associated with parameters of tumour progression and metastasis. Using reverse-transcriptase polymerase chain reaction (RT-PCR), Ets2 mRNA was detected in 69% of 181 breast carcinomas, 63% of 43 fibroadenomas and 47% of 43 specimens of normal breast tissue. Levels were significantly higher in carcinomas compared with normal breast tissue (P = 0.006). Using Western blotting, Ets2 protein was found to migrate as two bands with molecular masses of 52 kDa (p52) and 54kDa (p54). Levels of both proteins were significantly higher in the carcinomas compared with both fibroadenomas (P = 0.0001) and normal breast tissue (P = 0.0001). In the carcinomas, a significant relationship was found between the p52 and p54 form of Ets2 (r = 0.51, P < 0.0001; Spearman correlation). Also, in the carcinomas, a significant correlation was found between both forms of Ets2 protein and urokinase plasminogen activator (uPA) (for p52, r = 0.43, P = 0.0005, n = 68; for p54, r = 0.50, P = 0.0001, n = 68). As Ets2 binding sites are present on the uPA promoter, Ets2 may be one of the transcription factors regulating uPA expression in human breast cancer.

[1]  C. Hauser,et al.  Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors* , 2004, Journal of Biological Chemistry.

[2]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[3]  R. Cardiff,et al.  Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors , 2003, Molecular and Cellular Biology.

[4]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.

[5]  R. Tozer,et al.  Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells , 2002, Breast Cancer Research and Treatment.

[6]  J. Chambard,et al.  The Ets2 Transcription Factor Inhibits Apoptosis Induced by Colony-Stimulating Factor 1 Deprivation of Macrophages through a Bcl-xL-Dependent Mechanism , 1999, Molecular and Cellular Biology.

[7]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[8]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[9]  M. Hung,et al.  The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis , 2000, Nature Medicine.

[10]  V. Sementchenko,et al.  ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.

[11]  Michael C. Ostrowski,et al.  Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1Promoter* , 2003, The Journal of Biological Chemistry.

[12]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[13]  Michael C. Ostrowski,et al.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.

[14]  J. Hassell,et al.  Function of PEA3 Ets Transcription Factors in Mammary Gland Development and Oncogenesis , 2003, Journal of Mammary Gland Biology and Neoplasia.

[15]  B. Wasylyk,et al.  Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.

[16]  Margaret Kasten,et al.  Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.

[17]  R. Cardiff,et al.  A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.

[18]  J. Tentler,et al.  ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells , 2004, Oncogene.

[19]  Michael C. Ostrowski,et al.  ets-2 Is a Target for an Akt (Protein Kinase B)/Jun N-Terminal Kinase Signaling Pathway in Macrophages ofmotheaten-viable Mutant Mice , 2000, Molecular and Cellular Biology.

[20]  M. Duffy,et al.  Overexpression of the Ets-1 transcription factor in human breast cancer , 2004, British Journal of Cancer.

[21]  N. Brünner,et al.  Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients , 2003, Thrombosis and Haemostasis.

[22]  E. McDermott,et al.  Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.

[23]  Michael C. Ostrowski,et al.  Persistent Activation of Mitogen-Activated Protein Kinases p42 and p44 and ets-2 Phosphorylation in Response to Colony-Stimulating Factor 1/c-fms Signaling , 1998, Molecular and Cellular Biology.

[24]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[25]  G. Viglietto,et al.  Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. , 2001, Cancer research.

[26]  L. Khachigian,et al.  Ets-1 Protects Vascular Smooth Muscle Cells from Undergoing Apoptosis by Activating p21WAF1/Cip1 , 2003, Journal of Biological Chemistry.

[27]  G. Peters,et al.  Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence , 2001, Nature.

[28]  B. Vandenbunder,et al.  Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. , 1994, Invasion & metastasis.

[29]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[30]  Y. De Launoit,et al.  The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. , 2000, Advances in experimental medicine and biology.

[31]  M. Duffy.  Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .

[32]  E. Lengyel,et al.  Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences (*) , 1996, The Journal of Biological Chemistry.